Literature DB >> 12117453

Putting LIFE into hypertension.

Michael A Weber.   

Abstract

Entities:  

Year:  2002        PMID： 12117453     DOI： 10.1007/s11906-996-0004-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  5 in total

1.  Angiotensin blockade for hypertension: a promise fulfilled.

Authors:  Hans R Brunner; Haralambos Gavras
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

2.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1997-11-24

3.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

4.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

5.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.

Authors: 
Journal:  Lancet       Date:  2001-09-29       Impact factor: 79.321
  5 in total
  1 in total

1.  Prevention of diabetes and left ventricular hypertrophy with AT1 receptor blockade for hypertension.

Authors:  Robert M Carey
Journal:  Curr Hypertens Rep       Date:  2008-04       Impact factor: 5.369
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.